All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO TNF INHIBITORS: THREE YEAR RESULTS FROM A PHASE 3 STUDY (SPIRIT-P2)

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14160%2F20%3A00118264" target="_blank" >RIV/00216224:14160/20:00118264 - isvavai.cz</a>

  • Result on the web

    <a href="https://ard.bmj.com/content/79/Suppl_1/1158.1" target="_blank" >https://ard.bmj.com/content/79/Suppl_1/1158.1</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1136/annrheumdis-2020-eular.1482" target="_blank" >10.1136/annrheumdis-2020-eular.1482</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO TNF INHIBITORS: THREE YEAR RESULTS FROM A PHASE 3 STUDY (SPIRIT-P2)

  • Original language description

    Ixekizumab (IXE) is a high affinity monoclonal antibody that selectively targets interleukin-17A. In the SPIRIT-P2 study, IXE every 4 (Q4W) or 2 (Q2W) weeks was superior to placebo (PBO) in improving the signs and symptoms of psoriatic arthritis (PsA) at Week 24 in patients (pts) with prior inadequate response or intolerance to 1 or 2 tumor necrosis factor inhibitors (TNFi).

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30104 - Pharmacology and pharmacy

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2020

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Annals of the Rheumatic Diseases

  • ISSN

    0003-4967

  • e-ISSN

    1468-2060

  • Volume of the periodical

    79

  • Issue of the periodical within the volume

    79

  • Country of publishing house

    GB - UNITED KINGDOM

  • Number of pages

    1

  • Pages from-to

    1154

  • UT code for WoS article

    000555905003485

  • EID of the result in the Scopus database